Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 253

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 19
Chunk 253
---
)                                   
                                     As of March 31                                   
                                     2024                           2025              
 ──────────────────────────────────────────────────────────────────────────────────────
  Property, plant and equipment      ¥                   3,162      ¥         6,259   
  Goodwill                                               3,745                7,011   
  Intangible assets                  62                             33                
  Inventories                                            1,242      95                
  Trade and other receivables        767                            —                 
  Deferred tax assets                347                            —                 
  Other assets                       13                             —                 
  Total assets                       ¥                   9,337      ¥         13,397  
  Trade and other payables           ¥                     660      ¥         —       
  Deferred tax liabilities           307                            —                 
  Other liabilities                  442                            —                 
  Total liabilities                  ¥                   1,410      ¥         —       

The disposal groups held for sale consisted of the following and their associated fair value is classified as Level 3 in the fair value hierarchy as of March 31, 2024.

• The assets such as goodwill and property, plant and equipment were classified as held for sale during the fiscal year ended March 31, 2023, following an agreement Takeda entered into to transfer manufacturing operation of TACHOSIL in Austria. The transfer of the operation is completed in May 2024.

• Takeda entered into an agreement to divest Takeda’s entire shares of a wholly-owned subsidiary, Nihon Pharmaceutical Co. Ltd, and classified the corresponding assets and liabilities such as property, plant and equipment as held for sale.

In addition, during the fiscal year ended March 31, 2024, Takeda classified the assets and liabilities such as intangible assets and goodwill as held for sale related to an asset purchase agreement to transfer Instanyl and Matrifen and completed the divestiture in January 2024 (Note 5). The proceeds from this divestiture comprised the majority of Takeda’s proceeds from sales of business (net of cash and cash equivalents divested) in the consolidated statements of cash flows of JPY 19,959

The disposal groups held for sale consisted of the following and their associated fair value is classified as Level 3 in the fair value hierarchy as of March 31, 2025.

• The assets such as property, plant and equipment related to a manufacturing site in Orth, Austria was classified as held